文献速递冠心病血脂与心血管预防

冠状动脉钙化评分指导他汀分配:MESA研究解读

Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis.
PubMed 文献 · JAMA Cardiol · 2021-01-01

基于MESA前瞻性队列,纳入1688例中危ASCVD患者,评估风险增强因素与冠脉钙化(CAC)评分对ASCVD事件的关联。中位随访12.0年,CAC=0者各风险增强因素下ASCVD发生率多低于7.5/1000人年,CAC评分对事件判别与重分类改善最大,支持CAC作为风险增强评估的辅助工具指导他汀治疗。

要点

  • 中危患者CAC=0时,多数风险增强因素不使ASCVD风险超过他汀起始阈值。
  • CAC评分较单用风险增强因素对ASCVD事件判别改善最大(C统计量0.633 vs 0.678)。
  • CAC评分重分类改善净值为0.067,支持其辅助风险增强评估指导他汀分配。

核心结论

  • 在中危ASCVD患者中,CAC=0时风险增强因素的存在通常不使总体ASCVD风险超过推荐的他汀起始治疗阈值。
  • CAC评分显著改善ASCVD事件的判别与重分类,支持其作为风险增强因素评估的辅助工具。

研究设计与样本

  • 多民族动脉粥样硬化研究(MESA)为美国多中心基于人群的前瞻性横断面研究。
  • 基线数据收集于2000年7月15日至2002年7月14日,ASCVD事件随访至2015年8月20日。
  • 纳入45至75岁、无临床ASCVD或糖尿病、ASCVD中危(≥7.5%至<20.0%)、LDL-C 70至189 mg/dL者,共1688例。

主要发现

  • 1688例参与者平均(SD)年龄65(6)岁,男性976例(57.8%);白人648例(38.4%)、黑人562例(33.3%)、西班牙裔305例(18.1%)、华裔173例(10.2%)。
  • 722例(42.8%)CAC评分为0;有1至2个风险增强因素者CAC=0比例为45.7%,有3个及以上者为40.3%。
  • 中位随访12.0年(IQR 11.5-12.6),CAC=0者各单个风险增强因素下ASCVD未调整发生率均低于7.5事件/1000人年,但踝臂指数例外(10.4事件/1000人年,95%CI 1.5-73.5)。
  • CAC评分对ASCVD事件C统计量改善最大(0.633 vs 0.678),CAC的净重分类改善为0.067。

关键数值与推荐

  • 2018 AHA/ACC血胆固醇管理指南推荐对中危ASCVD个体使用风险增强因素评估并选择性使用CAC评分指导他汀分配。
  • 中危定义为ASCVD风险≥7.5%至<20.0%,LDL-C水平70至189 mg/dL。
  • CAC=0时,除踝臂指数外,各风险增强因素及组合(包括≥3个因素)的ASCVD发生率均低于7.5事件/1000人年。

临床怎么用

  • 对ASCVD中危患者,可先评估风险增强因素,再选择性行CAC评分以细化风险分层。
  • CAC=0且无踝臂指数异常等特殊情况时,风险增强因素的存在通常不使他汀起始风险超过推荐阈值。
  • CAC评分有助于更准确分类可能从他汀治疗获益的中危个体。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The 2018 American Heart Association/American College of Cardiology Guideline on the Management of Blood Cholesterol recommends the use of risk-enhancing factor assessment and the selective use of coronary artery calcium (CAC) scoring to guide the allocation of statin therapy among individuals with an intermediate risk of atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To examine the association between risk-enhancing factors and incident ASCVD by CAC burden among those at intermediate risk of ASCVD. DESIGN, SETTING, AND PARTICIPANTS: The Multi-Ethnic Study of Atherosclerosis is a multicenter population-based prospective cross-sectional study conducted in the US. Baseline data for the present study were collected between July 15, 2000, and July 14, 2002, and follow-up for incident ASCVD events was ascertained through August 20, 2015. Participants were aged 45 to 75 years with no clinical ASCVD or diabetes at baseline, were at intermediate risk of ASCVD (≥7.5% to <20.0%), and had a low-density lipoprotein cholesterol level of 70 to 189 mg/dL. EXPOSURES: Family history of premature ASCVD, premature menopause, metabolic syndrome, chronic kidney disease, lipid and inflammatory biomarkers, and low ankle-brachial index. MAIN OUTCOMES AND MEASURES: Incident ASCVD over a median follow-up of 12.0 years. RESULTS: A total of 1688 participants (mean [SD] age, 65 [6] years; 976 men [57.8%]). Of those, 648 individuals (38.4%) were White, 562 (33.3%) were Black, 305 (18.1%) were Hispanic, and 173 (10.2%) were Chinese American. A total of 722 participants (42.8%) had a CAC score of 0. Among those with 1 to 2 risk-enhancing factors vs those with 3 or more risk-enhancing factors, the prevalence of a CAC score of 0 was 45.7% vs 40.3%, respectively. Over a median follow-up of 12.0 years (interquartile range [IQR], 11.5-12.6 years), the unadjusted incidence rate of ASCVD among those with a CAC score of 0 was less than 7.5 events per 1000 person-years for all individual risk-enhancing factors (with the exception of ankle-brachial index, for which the incidence rate was 10.4 events per 1000 person-years [95% CI, 1.5-73.5]) and combinations of risk-enhancing factors, including participants with 3 or more risk-enhancing factors. Although the individual and composite addition of risk-enhancing factors to the traditional risk factors was associated with improvement in the area under the receiver operating curve, the use of CAC scoring was associated with the greatest improvement in the C statistic (0.633 vs 0.678) for ASCVD events. For incident ASCVD, the net reclassification improvement for CAC was 0.067. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, among participants with CAC scores of 0, the presence of risk-enhancing factors was generally not associated with an overall ASCVD risk that was higher than the recommended treatment threshold for the initiation of statin therapy. The use of CAC scoring was associated with significant improvements in the reclassification and discrimination of incident ASCVD. The results of this study support the utility of CAC scoring as an adjunct to risk-enhancing factor assessment to more accurately classify individuals with an intermediate risk of ASCVD who might benefit from statin therapy.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Patel J, Pallazola VA, Dudum R, et al. Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol. 2021. PMID: 34259820. doi:10.1001/jamacardio.2021.2321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。